BioMarin Acquires Alesta Therapeutics for $275 Million
BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal valued at up to $490 million, including an upfront payment of $275 million and potential additional payments tied to development milestones. The acquisition targets ALE1, an oral small molecule candidate for hypophosphatasia (HPP), a rare genetic bone disease affecting over 9,000 Americans. If approved, it would be the first oral treatment available for HPP, currently managed with injectable therapies. The transaction is expected to close in Q3 of 2026 and will be funded through BioMarin’s existing cash reserves. Alesta's non-ALE1 assets are set to spin out into a separate entity before closing, meaning no employees from Alesta will join BioMarin as part of the deal. BioMarin CEO Alexander Hardy emphasized that ALE1 aligns with their strategic focus on rare diseases and strengthens its clinical pipeline. Alesta’s CEO Ilan Ganot praised BioMarin's global capabilities in advancing treatments for HPP patients.
Tickers: $BMRN
Topics: clinical trials pharmaceutical rare disease treatment